Bayer Animal Health has taken over the marketing and sales of the antibiotic Nisamox (tablets containing Amoxicillin and Clavulanic Acid), from Fort Dodge Animal Health.
Under the new arrangement, the design of Nisamox tablet packaging will change to reflect the change of ownership, however, Bayer says the quality of the tablets and the competitive pricing remain unchanged.
Nisamox tablets are licensed for use in cats and dogs to treat infections of the skin, urinary tract, and respiratory tract caused by susceptible Staphylococci, and also to treat enteritis and urinary tract infections caused by susceptible E.coli.
Nisamox tablets will continue to be available in three strengths: 50mg, 250mg, and 500mg. For information on Nisamox tablets, contact your Bayer territory manager.
The first, carried out by Nanna Luthersson and colleagues and published online in the Journal of Equine Veterinary Science in March, evaluated the laminitis risk factors in a group of Danish horses and ponies.1 It confirmed that Cold-blooded type animals <149cm, such as certain native ponies, as well as those being kept on high quality pasture were at an increased risk of developing laminitis for the first time. It also highlighted the important role that a change in grass intake, in terms of both type and amount, may play at any time of the year not only the spring as commonly thought.
The second study, funded in part by the PetPlan Charitable Trust, British Veterinary Association Animal Welfare Foundation Norman Hayward Fund and the Laminitis Trust, was undertaken in conjunction with Nicola Menzies-Gow (Royal Veterinary College) and published online in the Equine Veterinary Journal (EVJ) in August. The study evaluated the risk factors for the development of laminitis prior to the occurrence of the disease.2 It identified that low concentrations of the adipose tissue derived hormone adiponectin, together with high serum insulin concentrations (at rest and as part of a diagnostic test for PPID) may predict an increased risk of future pasture-associated laminitis.
It is hoped that future studies will be able to generate more robust cut off values, which will more accurately predict future laminitis development in an individual animal.
The RVC in collaboration with Waltham is now taking this forward through a study in which these markers are measured regularly, in conjunction with a detailed management assessment, in a group of ponies with no known history of laminitis at the start.
Clare Barfoot RNutr and the research and development manager at Spillers said: "The Danish study gives us important practical facts about the susceptibility of cold-blooded types, and is particularly applicable to natives in the UK. The second study gives hope that there may soon be a test or series of tests that will help predict those at an increased risk of suffering from pasture associated laminitis in the future thereby reducing the number of animals affected by this debilitating condition. In the meantime until we fully understand the condition it is sensible to manage all the risk factors we currently know about, in particular keeping your horse at a healthy weight."
References
The study assessed contamination across 13 small animal practices using adenosine triphosphate (ATP) testing before and after delivery of a staff training session and standardised cleaning protocols.
Eleven practices were re-tested 70 days later and five practices were re-tested an average of 128 days later.
Samples were taken from reception areas, consulting rooms, preparation and diagnostic areas, wards, theatres, kitchens, laboratories, and staff areas, using Hygiena EnSURE Touch & UltraSnap Surface ATP Swabs.
The cleaning protocol involved the removal of biofilms using a degreasing agent, followed by routine cleaning with a standard veterinary disinfectant cleaner and fogging application of a certified veterinary disinfectant.
Before the intervention, average contamination levels in practices were 14.7 times higher than recommended thresholds.
Following the 45-minute staff training session and implementation of the standardised cleaning protocol, contamination levels reduced by 61% within 70 days and by 71% within 128 days.
Fomite surfaces — including door handles, kettles, and keyboards — showed the greatest improvement, with contamination levels reduced by 80%. General surfaces recorded a 56% reduction.
These findings indicate that a combination of staff training, refined cleaning protocols, and scheduled hygiene testing can significantly reduce contamination levels in practices and improve practice-level infection control.
Dr Neil Forbes, author of the study, said: “Once identified, most hygiene issues are readily addressed.
"Reservoirs of contamination, or indications of poor working practices, once detected, can be resolved.
"Longitudinal studies in human hospitals demonstrate that ATP reduction correlates with decreased nosocomial infection rates, ranging from 45–75% over 18 months to 5 years.”
The study recommends that practices appoint an Infection Control Champion, implement routine - ideally monthly - ATP testing, raise awareness with the whole team about infection sources, transmission routes, and risk management, and use two-step sanitation comprising cleaning followed by disinfection.
Reference
Novartis Animal Health has announced that it will no longer be manufacturing and supplying the enzootic abortion vaccine, Mydiavac.
The company reassures its customers that current stocks will continue to be distributed as smoothly as possible.
Virbac has launched Milpro, a palatable milbemycin / praziquantel-based broad-spectrum wormer for dogs and cats.
Milpro is offered in tablet sizes suitable for dogs, small dogs or puppies, cats and small cats or kittens for ease of dosing. It is presented in 4, 24 and 48 packs.
As an aid to owner education and compliance, packs of Milpro use 'Blippar Augmented Reality'. Owners download the Blippar app and scan the front of a pack of Milpro or a dispensing envelope, whereupon the pack becomes animated and various interactive options appear, including educational videos, a built in reminder system and other product information.
Simon Boulton MRCVS, Marketing Manager for Companion Animals at Virbac, said: "The practice team has a crucial role to play in reminding owners that regular worming is essential for their pet's health. With the introduction of Milpro, we are extending our parasiticide range and offering practices an alternative solution.
"With compliance such an issue, we want to use 21st century communication to help practices to get the message across. The result is the introduction of an interactive element to our packs with the use of the Blippar platform. It enables us to create 'Augmented Reality' experiences through which we can provide comprehensive information to owners in an eye-catching and easily accessible way with the aim of boosting compliance and, ultimately, welfare.
"We believe the combination of the small tablet sizes and the innovative packaging will prove attractive and convenient to owners, making Milpro a successful product for practices".
Practices can also request an interactive waiting room poster which enables owners to watch a video on the poster on the importance of worming.
RCVS CEO Lizzie Lockett said: "I am so proud of our performance in the Great Place to Work Awards and the efforts of everyone at the College, and especially our HR team, who have been tirelessly and creatively striving to make the College a wonderful place to work.
"Consistently being placed in the top 50 Great Places to Work is also a testament to the sustained hard work all of our employees and the important part they play in creating a supportive, interesting and good-humoured workplace.
"We are a service-led organisation and we want to make sure that we give our best to the veterinary professions and the general public. If our team enjoys the work, and the workplace, that will improve the service we are able to offer and, ultimately, benefit animal health and welfare."
Boehringer Ingelheim Vetmedica has launched Pexion (imepitoin) a novel treatment for canine idiopathic epilepsy.
Canine epilepsy can affect up to 5% of dogs6. In most dogs diagnosed with idiopathic epilepsy no underlying cause for the seizures can be found. While the condition can affect any dog, it is more common in young (one to five year old), purebred dogs such as Labradors, Golden Retrievers, German Shepherds, Boxers, Vizlas, Beagles, English Springer Spaniels, Irish Setters, Poodles and Dachshunds.
Boehringer says Pexion has a highly targeted mode of action1-3 to suppress a dog's seizures. It starts to work within a few hours and reaches steady state within three days4,5. Boehringer claims this will make it easier to stabilise epileptic patients. It also says there is no evidence of hepatotoxicity or liver-associated enzyme elevation, so repeated blood tests for liver enzymes or therapeutic levels are no longer required.4,5
Pexion is available in 100 mg and 400 mg tablets. The tablets are white, scored and divisible in half. Both tablet strengths are available in 100 tablet packs from veterinary wholesalers.
Jemima Mead, brand manager at Boehringer said: "Pexion is a ground-breaking new product which gives vets a new first-line treatment option for dogs with idiopathic epilepsy, improving the lives of newly diagnosed epileptic dogs and their owners by reducing the number of seizures and their impact on the patient's life".
To support the launch of the new product, Boehringer hosted an epilepsy webinar presented by neurologist Dr Holger Volk DVM PhD DipECVN FHEA MRCVS, recognised RCVS and European Specialist in Veterinary Neurology. The webinar is now available on demand at www.bi-academy.co.uk.
For further information on Pexion visit www.pexion.co.uk, contact your local Boehringer Ingelheim territory manager or telephone +44 (0)1344 746959.
The Disciplinary Committee of the Royal College of Veterinary Surgeons has dismissed a case against a Staffordshire veterinary surgeon, having found that his convictions under the Criminal Justice Act 1988 and the Public Order Act 1986 did not make him unfit to practise veterinary surgery.
At the one-day hearing, the Committee heard that Mr Richard Conlon of Warrendale Veterinary Care Centre, Biddulph, was convicted of one instance of common assault and one public order offence involving threatening, insulting or abusive language, both of which occurred during an altercation in a public house in Biddulph on 28 November 2009. The court ordered Mr Conlon to pay two fines of £300 each, a victim surcharge of £15, and £700 of court costs.
As the facts involved in Mr Conlon's offences had been proved by the court that convicted him, and Mr Conlon admitted to his convictions, the Committee considered only whether these offences made him unfit to practise veterinary surgery.
The Committee was advised that although the convictions were unrelated to Mr Conlon's professional practice, any criminal conviction may call into question a veterinary surgeon's fitness to practise if the conduct for which they are convicted raises doubts over their capability as a veterinary surgeon. Convictions that damage the wider public interest in the good reputation of the profession and public confidence can also raise questions about fitness to practise and may be considered.
Speaking on behalf of the Disciplinary Committee, Vice-Chairman Professor Sheila Crispin said: "In reaching our decision, it is important to emphasise that the Disciplinary Committee does not condone Mr Conlon's behaviour in any way. We accept the submission of the College 'that it is incumbent on any veterinary surgeon to act with decorum and not to engage in any violent, aggressive or intimidating behaviour,' and, on any view, for a veterinary surgeon to get involved in a brawl in a public house is unacceptable behaviour.
"In the Committee's judgment this was a one-off incident of brief duration with no premeditation on Mr Conlon's part; fortunately no significant injury was suffered by anybody involved. From the nature of the charges and the sentence of the court, it can be seen that this was at very much the lower end of seriousness and, as is accepted by the College, involves no concern about Mr Conlon's ability to practise as a veterinary surgeon."
The Committee ordered the charges be dismissed.
Merial Animal Health has launched Veloxa, a palatable broad spectrum dewormer for dogs, effective against roundworm, hookworm, whipworm and tapeworm.
Merial says Veloxa uses a proprietary technology which coats the bitter active ingredients in the beef-flavoured chewable tablets. In the company's palatability tests it achieved 97% acceptance.
Veloxa tablets are scored for accurate dosing and come in two sizes:
Christine Male, Product Manager of Veloxa said: "Merial has a strong heritage in anti-parasitics and understands how difficult it can be for pet owners to administer worming tablets, so we are extremely pleased to be able to offer Veloxa as part of the Merial anti-parasitics range."
The 'Room For Rabbits' campaign follows research in which 38% of vets said they think rabbits’ environment is the most neglected welfare need1, with over a quarter of the UK’s rabbits being kept in inadequate housing conditions, and almost half of them living alone2.
The RAW survey also found that 90% of vets believe that rabbits’ welfare in the UK is improving3.
Room for Rabbits will throw a spotlight on rabbits’ environment, with a variety of initiatives during RAW including vet blogs and videos on how to adapt bunnies’ housing for all seasons, boredom buster ideas, a competition to encourage owners to create a RAW ‘gold standard’ environment, and downloadable packs containing resources for practices to create their own RAW campaigns.
Holly Castle, Senior Brand Manager at Burgess Pet Care, RAAG member and organisers of RAW, said: “We are delighted that RAW continues to have a positive impact, with our survey showing that 90% of vets believe that the welfare of the UK’s rabbits is improving - but there is always more than we can do.
“Since the previous RAW campaign, we have successfully launched RAAG, which recognises that the welfare of these wonderful creatures needs to be high on the agenda year-round.
"By bringing together the expertise of the RAW partners, RAAG is focused on encouraging everyone involved with rabbits to support the first Good Practice Code for rabbits’ welfare in England to ensure it becomes enshrined in law.
"One of the ways to achieve this is through initiatives like RAW, which is the UK’s largest welfare campaign of its kind.
“We recognise that vets’ practices were really stretched last year due to the Covid-19 pandemic, which meant it was difficult to support campaigns like RAW.
"However, following a surge in demand for rabbit ownership in the UK during the past two years, it is vitally important that we educate more owners than ever before and continue to help improve rabbits’ welfare."
“The veterinary community plays a hugely important role in ensuring that owners have access to the right information, and we are urging practices to throw their support behind this year’s RAW to ensure that we reach as many owners as possible.
Professor Ian Ramsey, Past President of the BSAVA, which endorses RAW, said: "The BSAVA is once again delighted to support RAW and the theme of this year’s campaign.
"Rabbits remain one of the most misunderstood pets in the UK, but we are confident that vets across the UK will again show their support for this important campaign to improve the lives of pet rabbits.”
The RAAG is encouraging vets’ practices to sign up to receive updates about RAW at https://www.rabbitawarenessactiongroup.co.uk/raw-pack-reminder/.
Downloadable RAW vet packs will also be available from 6th June.
Dechra Veterinary Products has launched Cyclo Spray, an antibiotic spray for veterinary professionals treating hard to reach sites when handling cattle, sheep and pigs.
Dechra says the new product has been developed for use at any angle, even upside down.
Cyclo Spray (chlortetracycline hydrochloride 2.45%) is indicated for the treatment of superficial claw and hoof infections and the prevention of infections of superficial traumatic or surgical wounds.
Dechra Veterinary Products Brand Manager Emma Jennings said: "Vets dealing with livestock can often find that they are twisting themselves into awkward positions to get to hard to reach sites with traditional spray can treatments. Not only are they having to find the right angle to ensure the can works, but also potentially the treatment can drip or take time to dry.
"We've introduced Cyclo Spray to our portfolio to help combat some of those difficulties - it is a new 360 degree spray can allowing users to mark the site of application with confidence from whatever angle. It is non-drip, fast-drying with excellent adhesive characteristics and contains a non-toxic colouring agent."
Cyclo Spray is available in 211ml and 422ml can sizes. No withdrawal days are required for meat and milk.
To promote the launch of the new product, Dechra has also launched a competition giving entrants the chance to win a two day trip to London for two people to ride the London Eye and experience the capital from a 360 degree vantage point.
To enter the competition, with the prize including return rail travel, and dinner, bed and breakfast in a 4* hotel, visit www.dechra.co.uk to download an entry form.
Warwick Seymour-Hamilton, a former veterinary surgeon who practised in Kent, has had his third application for restoration to the Register refused by the RCVS Disciplinary Committee this week.
Mr Seymour-Hamilton was struck off in 1994 following an inspection of his premises, equipment and facilities in Orpington, which were found to be in such poor condition that it constituted a risk to the health and welfare of animals brought to the practice and brought the profession into disrepute.
Mr Seymour-Hamilton had made two previous restoration applications in July 1995 and June 2010. Both of these were refused on the grounds of poor preparation for re-entering practice life as, in both cases, he had made no attempt to engage in continuing professional development or visit and observe other veterinary practices.
Representing himself at this week's hearing, Mr Seymour-Hamilton said that, since the 2010 hearing, he had further developed an interest in herbal medicine and, after visiting a number of veterinary practices in continental Europe, had attended the College of Naturopathic Medicine in Dublin, gaining a qualification in herbal and naturopathic medicine. He told the Committee that he currently worked as a herbalist and naturopath with human patients but wanted to widen his work and research to include animal patients.
The Committee was concerned by his answers to a number of questions, Mr Seymour-Hamilton having described the hearing as an 'exploratory meeting' and indicating a lack of knowledge in a number of areas to do with veterinary practice and its regulation. The Committee felt that this demonstrated a fundamental lack of understanding as to its function and terms of reference.
Professor Noreen Burrows, chairing the Committee and speaking on its behalf, said: "The Committee expresses its surprise and concern at the lack of preparation for this hearing by the applicant, given that these issues have arisen at his previous restoration hearings, and that the result of a positive finding in favour of him would be his ability to practise unfettered as a veterinary surgeon forthwith."
In particular the Committee highlighted Mr Seymour-Hamilton's lack of understanding of the regulatory framework for veterinary practice as set out in the RCVS Code of Professional Conduct, the requirements of continuing professional development and what 'fitness to practise' meant, beyond the practical issues of his physical and mental capacity.
Professor Burrows added: "Based on all of the evidence available to the Committee it is very clear that he has failed to satisfy... that he is fit to be restored to the Register and this application is therefore dismissed."
The Committee's full findings and decision are available on the RCVS website (www.rcvs.org.uk/disciplinary).
This study was conducted in collaboration with the Waltham Centre for Pet Nutrition as part of a larger study, led by Prof Claire Hughes at the University of Cambridge Centre for Family Research.
Researchers surveyed 12-year-old children from 77 families with one or more pets of any type and more than one child at home. Children reported strong relationships with their pets relative to their siblings, with lower levels of conflict and greater satisfaction in owners of dogs than other kinds of pets.
The authors say this research adds to increasing evidence that household pets may have a major influence on child development, and could have a positive impact on children’s social skills and emotional well-being.
Pets are almost as common as siblings in western households, although there are relatively few studies on the importance of child-pet relationships.
Matt Cassells, lead researcher, said: "Anyone who has loved a childhood pet knows that we turn to them for companionship and disclosure, just like relationships between people. We wanted to know how strong these relationships are with pets relative to other close family ties. Ultimately this may enable us to understand how animals contribute to healthy child development."
He added: "Even though pets may not fully understand or respond verbally, the level of disclosure to pets was no less than to siblings.
"The fact that pets cannot understand or talk back may even be a benefit as it means they are completely non-judgmental. While previous research has often found that boys report stronger relationships with their pets than girls do, we actually found the opposite. While boys and girls were equally satisfied with their pets, girls reported more disclosure, companionship, and conflict with their pet than did boys, perhaps indicating that girls may interact with their pets in more nuanced ways."
Waltham researcher Nancy Gee, a co-author of the study, said: "Evidence continues to grow showing that pets have positive benefits on human health and community cohesion. The social support that adolescents receive from pets may well support psychological well-being later in life but there is still more to learn about the long term impact of pets on children’s development."
In 2014 ioLight co-founders, Oxford physicists Andrew Monk and Richard Williams, filed a patent application for a pocket-sized digital microscope with a performance that compares with expensive laboratory microscopes. They asked Cambridge Industrial Design to realise the product, briefing them that the device would need to deliver images with one micron resolution (required to view human or animal cells) onto a smartphone or tablet, be pocket-sized, easy to use, and economical to build in medium to high volumes.
One of the biggest challenges was in making the unit pocket-sized, which meant it had to be foldable, something which could have led to a loss in the rigidity needed to achieve high resolution images. This challenge was overcome with the use of a single hinge which the company says makes the ioLight both portable and robust.
Alex Jones, Managing director of Cambridge Industrial Design said: "We recognised immediately this was a great idea but the design brief was certainly a challenge. Fortunately, challenges can sometimes bring out the best in designers. The final design is a real success both aesthetically and ergonomically, and this award is a fantastic acknowledgement for the design process and the final product that we have created together with ioLight."
ioLight is also celebrating another success: closing its second round of equity funding after raising £320k from 335 investors on the Crowdcube platform (128% of the initial target).
The company says the new funding will allow it to promote the microscope to a wide range of target markets including veterinary surgeons, education, laboratory and field research, museums and public engagement as well as to international markets.
Andrew Monk, ioLight’s co-founder said: "The product is so simple to use that it is the ideal communication tool for explaining science to the public, students and customers. The microscope lets everyone see the same image so the discussion is about the picture not the tools. It’s a perfect fit for government public engagement campaigns, which are well funded at the moment. We are absolutely delighted that this funding provides us with the opportunity for both product development and to reach out and make microscopy available to so many more people."
Faecal calprotectin is a calcium-binding protein released into the gut lumen predominantly by neutrophils, and to a lesser extent by monocytes and macrophages, during intestinal inflammation.
Its presence in faeces reflects the degree of neutrophilic infiltration in the gut mucosa, making it a useful biomarker for identifying intestinal inflammation.
Faecal calprotectin lateral flow testing is already used in human health and included in the NICE guidelines for the management of inflammatory bowel disease (IBD)1.
Determining the underlying cause of chronic diarrhoea, vomiting and weight loss in cats and dogs can be complex, often requiring invasive procedures such as endoscopy or biopsy - both of which carry cost, risk, and sometimes practical limitations in general practice.
GIQuest is designed to offer a non-invasive, rapid alternative to support clinical decision-making.
Carus says that whilst not a replacement for histopathology, faecal calprotectin concentrations have been shown to correlate with disease severity in dogs and cats, as measured by tools such as the Canine Chronic Enteropathy Clinical Activity Index (CCECAI).2
New data from the University of Bristol Vet School appears to confirm the test’s ability to differentiate dogs with histologically-confirmed inflammatory enteropathy from healthy controls with high sensitivity (94%) and specificity (96%) using a score threshold of 3mg/kg.2
Carus says the test also performed well in cats, distinguishing those with inflammatory enteropathy from healthy controls with a specificity of 100% and sensitivity of 92%.
In addition, the test detected elevated calprotectin levels consistent with inflammatory gastroenteropathy in 25% of dogs receiving oral NSAIDs, which highlights its potential not only in long-term monitoring but also early in treatment when GI side effects may first emerge.
Jolian Howell of Carus Animal Health said: “Faecal calprotectin testing can provide additional clarity in a range of clinical scenarios.
"It is particularly useful when diagnosing and managing suspected inflammatory enteropathy or food related reactions and for monitoring or screening for GI side effects of oral non-steroidal anti-inflammatories in long term OA therapy regimes.”
The Bristol study also showed that dogs with food-responsive enteropathy had a significant drop in calprotectin concentrations following dietary change, reinforcing the test’s role in tracking treatment response.
Georgie Louca, Veterinary Business Manager for Carus Animal Health, added: ”By providing a measurable, visual indicator of intestinal inflammation, GIQuest also helps support client communication and can improve compliance during treatment or dietary trials.”
GIQuest is designed for use in practice, including during consultations, delivering colour-coded results in 15 minutes.
GIQuest is now available to veterinary practices across the UK and can be ordered through veterinary wholesalers NVS, Covetrus and MWI.
https://carusanimalhealth.com/giquest
Research amongst veterinary surgeons by Janssen Animal Health, maker of Cavalesse oral and Cavalesse topical, has revealed that owners could be doing more harm than good when it comes to managing sweet itch in their horses.
92% of vets questioned are aware that people follow old wives' tales by administering lotions and potions such as garlic and olive oil to ward off flies during the summer sweet itch season, when garlic actually has the opposite effect of attracting them.
According to Janssen, it is thought that only a quarter of horse owners are aware that it is important to carry out preventative measures before the start of the midge season to help alleviate sweet itch. 14% of people are thought to go to their vet for advice on sweet itch, while 30% seek help from their country store or tack shop, 27% search for information on websites and 26% ask other horse owners for guidance. This is despite the fact that 92% of those questioned believe that sweet itch would clear up quicker if people sought advice from their veterinary surgeon.
Nicki Glen, marketing manager at Janssen Animal Health said: "Sweet itch can be an incredibly difficult and frustrating condition to manage, however horse owners do not tend to seek advice from their vets. It is therefore important to educate horse owners while you are on yard visits with pro-active advice on the condition for the long-term health and welfare of horses."
Cavalesse is a natural food supplement containing a specialised formulation of water-soluble vitamins and minerals, including nicotinamide. Once a month the contents of each sachet are dissolved in water to form an oral solution, which can be administered daily via a special pipette, either by sprinkling over a small handful of feed or adding to a treat such as a sugar lump. Janssen says the supplement helps horses maintain a healthy skin and promotes normal immune function in horses prone to summer allergies.
Cavalesse Topical is a skincare gel that can be used in combination with the Cavalesse solution. The gel can be applied to the skin to help support natural immunity from the outside, whilst the oral solution works in partnership from the inside.
For further information on Cavalesse and Cavalesse Topical please contact your Janssen Animal Health account manager or phone 01494 567555.
Petplan has announced the results of a survey which shows that with less than a week to go before microchipping becomes compulsory in England, Scotland and Wales, there is still confusion about the law amongst pet owners.
In the survey of 2,000 British dog owners, 25% had not heard of the new law and 40% didn't know that it also requires owners to keep their microchip details up to date.
40% of respondents said they'd be happy to pay over £500 as a reward if their dog went missing. Despite this, 40% of those who were aware of the new law but had yet to chip their dogs admitted they had not done so because of reservations about the cost of the procedure.
The survey also highlighted the fact that even the most careful of owners lose their dogs. Nearly 40% of losses reported in the survey happened when the owner was taking their pet on a daily walk and 47.1% of respondents reported having a dog escape from an apparently secure garden.
The survey also found that a third of lost dogs came to harm while missing, most of which (84.8%) needed veterinary care.
According to Petplan, despite more than half of dog owners citing expensive veterinary bills as one of their biggest concerns around dog ownership, over 45% of respondents reported not having their dogs insured.
Petplan has published information for pet owners about the new microchip law here: petplan.co.uk/microchip-dog-law-info.
The RCVS has launched a new College honour, the RCVS Queen's Medal.
RCVS President Col Neil Smith said: "The Queen's Medal will be the most prestigious honour that the RCVS can bestow upon a veterinary surgeon and will be reserved for those whose distinguished careers and outstanding lifetime achievements deserve wider recognition."
The honour was created following a review of the RCVS honours system, which demonstrated the need for a new aspirational award.
The RCVS wrote to the Cabinet Office last year, together with letters of support from Peers and MPs, many of whom attended the reception, to request permission to name this new honour after Her Majesty the Queen.
Col Smith said: "We are honoured that Her Majesty has supported the proposal and allowed the College to name the award after her, and express our sincere thanks to those Parliamentarians who supported our endeavour."
The first RCVS Queen's Medal will be presented at RCVS Day in July 2014. The nomination form for the Queen's Medal can be found at www.rcvs.org.uk/Queensmedal.
João, who graduated from Portugal’s Oporto University in 2009, was recruited from the University of Liverpool, where he was a lecturer in Small Animal Cardiology.
Willows Clinical Director Toby Gemmill said: "This is an exciting time for us. As part of our new extension, our state-of-the-art cardiology suite is now open and fully operational, while we have also appointed a hugely knowledgeable and experienced cardiologist to join the team.
"It is further evidence of our continued commitment to invest in top talent and the best facilities so we can provide the highest standards of care and treatment."
João said: "I’m very pleased to have joined a centre of excellence like Willows and to be working in the fantastic new cardiology suite.
"I enjoy all aspects of medical and interventional cardiology but I have a particular interest in feline cardiomyopathies, cardiorenal syndrome and atrial fibrillation."
Felpreva contains emodepside and praziquantel, with tigolaner, a novel bispyrazole active ingredient.
Felpreva is licensed for treatment of cats with, or at risk from, mixed parasitic infestations/infections.
Vetoquinol points to a survey revealed conducted last year in which 43% of cat owners said that giving parasite protection to their cat makes them feel guilty, stressed, or worried1.
Felpreva provides an option to reduce the frequency of treatments, lessening stressful interactions between owners and their cats.
Vetoquinol says that with Felpreva’s convenience and longer-lasting flea and tick protection, it aims to help support compliance and thus improve the wellbeing of feline companions.
Helen Hunter, Senior Product Manager at Vetoquinol UK, said: “The launch of Felpreva is a truly proud moment for Vetoquinol, demonstrating our expertise, passion, and commitment to innovation in this essential category of companion animal medicine.
"It will allow us to safeguard the health of cats by bringing longer-lasting protection, convenience, and ease of use – for both pet owners and veterinary professionals.
"At a time when vets are treating more pets than ever before, the need for a breakthrough endectocide solution like Felpreva has never been greater.”
Felpreva is in wholesalers now.
For more information, contact your local Vetoquinol representative.
Boehringer Ingelheim Vetmedica has launched Semintra, a new liquid treatment for cats with chronic kidney disease (CKD).
The active ingredient in Semintra is telmisartan, the first angiotensin receptor blocker to be licensed in veterinary medicine.
Like benazepril, Semintra is indicated for the reduction of proteinuria associated with CKD in cats. Boehringer says it has a highly targeted mode of action that provides rapid and reliable reduction of proteinuria in cats with chronic kidney disease. The company adds that it is well tolerated and almost exclusively excreted in the faeces, so elimination is not dependent on renal function.2
Above all, Boehringer is highlighting the how easy the treatment is to use, pointing to a study that has shown it is well accepted by more than 90% of cats.1,3
Martha Cannon, RCVS Specialist in Feline Medicine at the Oxford Cat Clinic, has already used Semintra in cats with CKD. She said: "For us at the Oxford Cat Clinic, ease of use is an enormously important part of any product that we use for cats. From our personal experience, we found that Semintra is very well accepted by cats, with owners finding it very easy to give and to build into their cat's daily treatment plan."
Semintra is available from veterinary wholesalers as a 4mg/ml oral solution. There is one 30 ml bottle size which will last the average 4kg cat 30 days.
A few CKD facts provided by Boehringer:
For further information on Semintra visit www.semintra.co.uk, contact your local Boehringer Ingelheim territory manager or telephone +44 (0)1344 746959.
BVA President Malcolm Morley said: “Judging this competition has been genuinely both extremely enjoyable and really difficult.
"The entries this year have absolutely surpassed expectations and the level of talent on display is amazing.
"However, the photographs we have chosen are all well worthy of being finalists.
"From photos that made us laugh out loud, to others that made some of us feel close to tears, they evoked a range of emotions, but we were also impressed by the quality of the images, the creativity of the photographers and the composition of the photos, as well as the stories behind the lens.
The finalists are:
Vets at work
All creatures great and small
Happy pets that make us smile
The winners will be announced at BVA Live at Birmingham’s NEC in May, where this year there is also an opportunity for BVA Live delegates to vote for their favourite image from the shortlist, with a new ‘People’s Choice’ winner being announced in the weeks following the event.
The awards are based on more than 11,000 pet owner reviews submitted to VetHelpDirect.com over the past 12 months.
The reviews cover 2,500 veterinary practices around the UK, with awards given to the practices with the highest number of four and five-star reviews from customers.
Tracey Morley Jewkes, Managing Director of Willows, said: “I am so proud of our team here and it’s fantastic to have won such a prestigious award based on client reviews.
"It was fabulous to receive such wonderful feedback as part of this award process. Our team at Willows is one of the best in the world, and we continue to strive for excellence in all that we do, providing the very highest standards of veterinary care to our patients, their owners and our referring vets."
Susie Samuel, managing director of VetHelpDirect.com, said: “The Best UK Vet awards are now in their eighth year and are a fantastic way to illustrate the strength of veterinary care in the UK.
“The awards are based on real-time customer reviews written over the past calendar year and recognise the very best veterinary practitioners.
“For animal owners, choosing a vet can be an anxious time, having access to reviews from other owners cuts down that anxiety. A vet who has been positively reviewed a number of times by different owners is clearly trusted and we know this provides peace of mind for new customers.
"The awards are categorised by geographical region, and also by type of practice and we have been delighted by the diversity of practices reviewed positively by their customers this year."
The silver award went to St Anne's Veterinary Group and the bronze award winning practice was Mayow Veterinary Surgery.
Photo: Toby Gemmill, Willows clinical director, Deputy Mayor of Solihull, Councillor Flo Nash, Tracey Morley Jewkes, managing director of Willows and Susie Samuels, founder and CEO VetHelpDirect
Elanco Animal Health has announced the launch of Kexxtone this month, a new treatment which it claims can reduce the incidence of ketosis in dairy cows by 74%* following a single treatment.1
Kexxtone is a targeted solution for any dairy cow or heifer that is expected to develop ketosis around the period of calving. It is administered as a bolus,and provides coverage during the main risk period for the condition.
Ketosis often goes undetected because the signs are not immediately apparent. However, it is a common condition, affecting around 30% of cows2 and has a negative impact upon cow health, fertility and milk production. Ketosis can result, on average, in milk losses of around 350-500 litres per cow4 per lactation. The cost of production losses and disease related consequential losses due to subclinical ketosis has been estimated at around 250-600 EUR per cow.5
Elanco says this new approach is likely to significantly expand the array of options open to vets actively involved in dairy herd health management. Kexxtone comes with the benefit of a zero day milk and meat withdrawal3 and the formulation is based on monensin - a molecule with a long history of beneficial use.
According to the company, Kexxtone uses novel technology to allow a continuous and regular release of the active ingredient into the rumen which forms a gel when exposed to rumen fluid. This gel is progressively released into the rumen by a pressure sensitive spring in the Kexxtone device. The active ingredient shifts the microbial balance in the rumen to produce more of the glucose precursor propionic acid, therefore increasing glucose delivery and ultimately increasing the energy available to the cow. This improvement in energy utilisation buffers dairy cows against the tendency to drop into negative energy balance during the transition period around calving and early lactation - the major cause of ketosis.
Mike Steele, Technical Consultant at Elanco said: "Kexxtone offers an exciting opportunity in which everyone wins - vets who can offer positive interventions able to make a big impact on the bottom line, are going to be increasingly integral to their farm clients' herd health planning framework. It's no longer just about nutritional intervention and emergency salvage; it's about being able to proactively easily measure the true herd prevalence of ketosis and where appropriate, take preventative targeted action to really make a difference."
Kexxtone is available to order now from veterinary wholesalers - for further information contact the Elanco Territory Manager or call Elanco Animal Health on 01256 353131.
Ms Mulvey faced a number of charges relating to the treatment of a cat called Spooky: that she failed to provide Spooky’s owner, Mrs Parsons, with either Spooky’s lab results or an adequate explanation as to why they could not be provided; that she failed to respond adequately or at all to communications from Mrs Parsons; that she failed to respond to requests from the College for information relating to Continuing Professional Development (CPD), her professional indemnity insurance (PII), and her correspondence with Mrs Parsons.
At the beginning of the hearing Dr Mulvey admitted the facts to all the charges, and accepted that they constituted disgraceful conduct in a professional respect. The Committee had been provided with written evidence from Mrs Parsons, her husband, and four College staff, namely Gemma Crossley, Maria Fearon, Robert Girling and Michael Hepper.
Mrs Parsons provided a statement in which she spoke of how, in August 2016, she had taken Spooky to CornYard Veterinary Centre for a skin irritation where she was seen by Dr Mulvey.
Dr Mulvey decided to take blood tests and send them to the laboratory, but they agreed to defer them actually being tested until Mrs Parsons gave permission. Mrs Parsons then returned to the practice with Spooky to take said samples, after which followed a series of attempts to contact Dr Mulvey for the test results. Finally, in October, she demanded a refund, after which she began a small claim in County Court.
Mr Parsons went to the practice at the beginning of December 2016 and obtained the refund. At this point Mrs Parsons made a complaint to the College. The Committee received information from Mr Parsons, who corroborated the facts of the complaint, and from College staff who confirmed the many attempts to contact Dr Mulvey, starting with requests for documents by Ms Crossley and Ms Fearon, repeated requests for CPD and PII information from Mr Girling, and finally a hand-delivered letter by Mr Hepper, during which he learnt that her PII had lapsed at the beginning of 2017.
The College submitted that Dr Mulvey’s conduct fell far below the standard expected of a veterinary surgeon. It submitted that failing to provide the test results and communicate with the Parsons could have had a negative impact on animal welfare and damaged the reputation of the profession, while having PII is a fundamental obligation of the RCVS Code of Professional Conduct. Finally, not responding to the College about the concern raised, CPD or PII compromised the College’s ability to maintain public confidence in its regulatory processes.
The Committee considered that no harm had actually come to Spooky and that there were problems with the testing laboratory which slowed down the process. In addition, some of the lack of communication was due to a receptionist not following protocol, and Dr Mulvey was going through a particularly difficult part of her life and was clinically understaffed. The Committee heard from four different character witnesses, and were given 16 more written testimonials.
The Committee heard that in 2013 there had been complaints from three separate clients, all of which concerned Dr Mulvey’s failure to communicate and to process insurance claim forms, after which she agreed to participate in the Performance Protocol and entered into undertakings with the College.
The Committee having considered all the facts and background circumstances found that Dr Mulvey’s conduct was disgraceful in a professional respect.
The Committee went on to consider what sanction was appropriate. In reaching its decision the Committee took into account a number of aggravating factors, namely that there was a slight risk to the health of Spooky and that the disgraceful conduct occurred over a prolonged period of time. The Committee also considered that there was blatant disregard of the role of the RCVS and the systems regulating the profession.
In determining the sanction the Committee also considered mitigating factors, including that Dr Mulvey, apart from those previous concerns, had a long and unblemished career and that she’s made a huge difference to the health of the animals within her care. She also admitted her shortcomings, and had very impressive references.
The Committee therefore determined to postpone its decision on sanction for a period of one year on condition that Dr Mulvey enter into the following undertakings:
To agree to the appointment of a veterinary surgeon as a work place supervisor by the College and meet with them at least once every month
Allow the supervisor access to all aspects of running of the practice and to implement any recommendations made by the supervisor relating to the administration of the practice and the provision of out of hours’ cover.
To allow the supervisor to provide a report in relation to the matters set out in 2 above to the RCVS at least one month before the resumed hearing of this case.
To appoint within two months an experienced Practice Manager (who does not need to be full time).
To enrol in the voluntary Practices Standards Scheme and to achieve the Core standards of the Scheme within the next 12 months.
To submit a plan to the supervisor of CPD for the next twelve months within one month of agreeing to these undertakings. The plan should then be implemented and shall include aspects of practice management.
To pay all of the costs of complying with the undertakings, with the exception of the costs associated with the appointment and performance of the supervisor.
Ian Green, chairing the Disciplinary Committee and speaking on its behalf, said: "The Committee recognised that Dr Mulvey has been subject to undertakings before and yet committed the disgraceful conduct the subject of this inquiry. But it bore in mind the context of that conduct and it observes that the undertakings previously imposed in reality address a particular aspect of her practice.
"This Committee hopes that when the matter is relisted before it, the Respondent will be able to demonstrate that she has finally been able to address her administrative shortcomings. If she cannot do so, she will know that the Committee that sits on her case at the resumed hearing is likely to have more restricted options for disposal of her case."